-
Arcturus Therapeutics NASDAQ:ARCT Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (209 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation.
Location: | Website: arcturusrx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
311.8M
Cash
237.2M
Avg Qtr Burn
-15.02M
Short % of Float
18.47%
Insider Ownership
8.46%
Institutional Own.
95.83%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ARCT-154 Details COVID-19 | NDA Acceptance for review | |
ARCT-032 Details Cystic fibrosis, Lung disease | Phase 2 Data readout | |
ARCT-810 Details Ornithine transcarbmylase deficiency, Urea cycle disorder | Phase 2 Data readout | |
ARCT-2138 Details Influenza | Phase 1b Data readout | |
ARCT-2304 Details H5N1 avian influenza | Phase 1 Initiation | |
ARCT-021 Details COVID-19 | Failed Discontinued |